L&G Pharma Breakthrough UCITS ETF (AMS:BIOT)
Netherlands · Delayed Price · Currency is EUR 11.67
-0.02 (-0.15%)
At close: May 22, 2026
25.13% (1Y)
| Assets | 16.16M |
| Expense Ratio | 0.49% |
| PE Ratio | 17.88 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +25.13% |
| Volume | n/a |
| Open | 11.76 |
| Previous Close | 11.69 |
| Day's Range | 11.76 - 11.76 |
| 52-Week Low | 9.00 |
| 52-Week High | 12.20 |
| Beta | n/a |
| Holdings | 41 |
| Inception Date | Jan 23, 2018 |
About BIOT
BIGT.L was created on 2018-01-23 by L&G . The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 18.57m in AUM and 37 holdings. The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Asset Class Equity
Category Health Care
Stock Exchange Euronext Amsterdam
Ticker Symbol BIOT
Provider L&G
Index Tracked Solactive Pharma Breakthrough Value Index
Performance
BIOT had a total return of 25.13% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.59%.
Top 10 Holdings
32.28% of assets| Name | Symbol | Weight |
|---|---|---|
| Travere Therapeutics, Inc. | TVTX | 4.30% |
| Jazz Pharmaceuticals plc | JAZZ | 3.49% |
| Pharma Mar, S.A. | PHM | 3.26% |
| United Therapeutics Corporation | UTHR | 3.10% |
| Royalty Pharma plc | RPRX | 3.09% |
| Zevra Therapeutics, Inc. | ZVRA | 3.06% |
| Mirum Pharmaceuticals, Inc. | MIRM | 3.06% |
| Swedish Orphan Biovitrum AB (publ) | SOBI | 3.02% |
| argenx SE | ARGX | 2.98% |
| Ultragenyx Pharmaceutical Inc. | RARE | 2.92% |